Tectonic therapeutic presents complete results for positive phase 1b clinical trial of tx45 in patients with group 2 pulmonary hypertension in hfpef in late-breaking presentation at esc heart failure 2025

Watertown, mass., may 17, 2025 (globe newswire) -- tectonic therapeutic, inc. (nasdaq: tecx) (“tectonic”) today announced the complete results from part a of the phase 1b clinical trial of tx45 in patients with group 2 pulmonary hypertension in heart failure with preserved ejection fraction (“ph-hfpef”), which are being presented in a late-breaking, oral session at the european society of cardiology (esc) heart failure 2025 congress being held in belgrade, serbia. the results include the full cohort of 19 patients in part a of the phase 1b trial of tx45, tectonic's lead asset and a long-acting relaxin therapy. interim data for 16 patients in the phase 1b trial was previously reported in a press release on january 30, 2025.
TECX Ratings Summary
TECX Quant Ranking